SK Bioscience Partners with Brazil's Eurofarma to Target Latin American Market

SK Bioscience is set to intensify its push into the Latin American market, leveraging its epilepsy treatment, cenobamate, through a new strategic partnership with Brazilian pharmaceutical firm Eurofarma. The Memorandum of Understanding (MOU) was officially signed in Sao Paulo, coinciding with South Korean President Yoon Suk Yeol's state visit to Brazil.

This collaboration marks a significant step for SK Bioscience, as its CEO, Dong Hoon Lee, was the only executive from the pharmaceutical and biotech sector to join the economic delegation. This participation underscores the importance of the Brazilian market and the broader Latin American region for the company's global expansion strategy.

The agreement signifies a concerted effort to introduce and distribute cenobamate, a treatment for epilepsy, across Latin America. By partnering with Eurofarma, a well-established player in the region, SK Bioscience aims to navigate local regulatory landscapes and market dynamics more effectively.

The company's focus on cenobamate highlights its commitment to addressing neurological disorders globally. The partnership with Eurofarma is expected to facilitate broader patient access to this important medication, strengthening SK Bioscience's presence and impact in key international markets.